Skip to content
Companies

Trinity Nuclein Series C Investors

Investment vehicle backing a rapid PCR test maker

Raised to date

$2.3M

of $15M offered across 1 Form D filing

Still open
$12.7M
Investors
23
Last filed
Feb 28, 2025

About

Nuclein is an innovative medical device company that specializes in the development of rapid diagnostic testing technologies. Founded in 2017 and based in Austin, Texas, Nuclein addresses the critical need for fast, accurate, and accessible testing for infectious diseases.

Nuclein stands out by providing lab-quality PCR test results in just 15 minutes at the point of care, making advanced testing accessible and efficient.

Funding

  • EquityFiled Feb 28, 2025Form D
    $2.3M/ $15M

Product

DASH® Rapid PCR System

Rapid Diagnostics

The DASH® Rapid PCR System is a cutting-edge diagnostic tool that enables healthcare professionals to deliver lab-quality PCR test results in a rapid timeframe of just 15 minutes. Designed for use at the point of care, this system significantly enhances the speed of infectious disease diagnosis, providing immediate results to both practitioners and patients.

  • Low-cost testing
  • Highly sensitive and specific results
  • Robust multiplexing capabilities across various sample types

Built for

Healthcare providers, clinics, hospitals, and at-home consumers

People on file